RNA at a glance
Atrium Therapeutics, Inc. (RNA, SEC CIK 2093101) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as September 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Atrium Therapeutics, Inc. (RNA) shares worth $40.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 22 funds
- $40.7M · −1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Collaboration revenue $15.3M, up $3.0M YoY, driven by a $15.0M BMS milestone
- Net loss $4.3M vs $0.0M YoY, with operating expenses $22.0M vs $12.6M
- Best program: ATR 1086 R&D spending $3.1M, up from $2.1M YoY
- Operating cash outflow $60.4M, cash and equivalents $44.6M, short-term investments $187.5M
- October PIPE generated $46.5M net proceeds, with proof-of-concept data anticipated in second half of 2027
Risk Factors
- Newly added financing risk: October 2026 Offering sold 5,170,384 shares and warrants, diluting existing stockholders
- Most material regulatory update: FDA cleared ATR 1072 IND in July 2026, but leadership changes may increase development uncertainty
- Compliance exposure: Federal Anti-Kickback Statute and False Claims Act violations could trigger civil or criminal penalties
- Near-term execution risk: First Corventis Phase 1/2 patient dosed in October 2026, with rare cardiac populations complicating enrollment
- Liquidity risk: $44.6 million cash and $187.5 million short-term investments fund operations for at least 12 months
AI summary of the RNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- First patient dosed in Phase 1/2 Corventis trial for PRKAG2 syndrome, with initial proof-of-concept data expected in the second half of 2027
- Nonclinical ATR 1072 data showed reversal of cardiac glycogen accumulation and improvements in hypertrophy and ECG conduction measures
Item 7.01: Regulation FD Disclosure
- Upcoming November 6, 2026 poster presentation at HCMS during American Heart Association Scientific Sessions 2026
- Investor relevance: conference data may influence clinical-development expectations and Atrium’s valuation
Item 8.01: Other Events
- New mouse-model data to be presented November 6, 2026, at AHA Scientific Sessions in Chicago
- Single-dose mATR 1072 reversed cardiac glycogen accumulation after established disease in mice
Item EX-99.1: Item EX-99.1
- Atrium will present preclinical ATR 1072 data at AHA Scientific Sessions on November 6, 2026
- Mouse surrogate mATR 1072 reversed cardiac glycogen accumulation and improved hypertrophy and ECG abnormalities
Item EX-99.2: Item EX-99.2
- Investor presentation outlines Atrium’s post-launch progress since February 2026, including ATR 1072 trial clearance and first patient dosing
- ATR 1072 Phase 1/2 Corventis trial targets PRKAG2 syndrome, with approximately 37 participants and initial proof-of-concept data expected in 2H 2027
Item 8.01: Other Events
- First patient dosed in Phase 1/2 Corventis trial of ATR 1072 for PRKAG2 syndrome
- Clinical-stage milestone advances lead program into human testing
Item EX-99.1: Item EX-99.1
- First patient dosed in Corventis, a Phase 1/2 trial testing ATR 1072 for PRKAG2 syndrome
- Approximately 37 participants planned across dose-escalation and expansion cohorts
AI summaries of RNA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for RNA
Don't miss the next RNA filing
- Alerts as it files. A push when RNA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut RNA, by share count.
- Ask anything. An AI agent that reads every RNA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Winslow Brendan R. | F | Sep 18, 2026 | 6,742 | $8.95 |
| Boyce Sarah | F | Sep 18, 2026 | 126,418 | $8.95 |
| Hughes Steven George | F | Sep 18, 2026 | 21,459 | $8.95 |
| Younis Husam | F | Sep 18, 2026 | 11,216 | $8.95 |
| Hoyos Rocio Martin | F | Sep 18, 2026 | 8,320 | $8.95 |
| Kenney Stephanie | F | Sep 18, 2026 | 2,375 | $8.95 |
| Flanagan W. Michael | F | Sep 18, 2026 | 22,812 | $8.95 |
| Gallagher Kathleen P. | F | Sep 18, 2026 | 11,632 | $8.95 |
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate RNA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $40.7M |
| Q2 2026 | 23 | $75.4M |
| Q1 2026 | 21 | $71.2M |
- Bank of America Corp+335.0K (+252%)
- Citadel Advisors LLC+150.8K (+223%)
- Two Sigma Investments+81.9K (+24%)
- Morgan Stanley+38.2K (+91%)
- State Street Corp+19.3K (+7%)
- T. Rowe Price Group−833.0K (-57%)
- BlackRock−229.0K (-16%)
- AQR Capital Management−141.3K (-82%)
- Millennium Management−52.9K (-26%)
- Goldman Sachs Group−10.1K (-3%)
- Prudential Financial+46.5K
- Franklin Resources−56.7K
- FMR LLC (Fidelity)−33.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 66 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
RNA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Oct 27, 2026 | - | Analysis | - |
| 8-K | Oct 9, 2026 | - | Analysis | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| SC 13G | Apr 27, 2026 | - | - | |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
| 4 | Apr 22, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
RNA SEC filings: frequently asked questions
Which institutions hold RNA stock?
As of September 30, 2026, the largest Atrium Therapeutics, Inc. (RNA) holders among the 13F filers tracked by SignalX were BlackRock ($10.1 million), Vanguard Capital Management LLC ($6.0 million), T. Rowe Price Group ($5.3 million), Bank of America Corp ($3.9 million), Two Sigma Investments ($3.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did RNA report in its latest 8-K?
Atrium Therapeutics, Inc. (RNA) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest RNA SEC filings?
Atrium Therapeutics, Inc. (RNA) filed a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on September 22, 2026.
What is RNA's SEC CIK number?
Atrium Therapeutics, Inc. (RNA)'s SEC Central Index Key (CIK) is 2093101. EDGAR lists every RNA filing under that number.
Ask anything about RNA
The research agent reads RNA's filings, financials, insider trades and 13F holders, then answers with sources.